What is HC Wainwright’s Estimate for Evolus FY2025 Earnings?

Evolus, Inc. (NASDAQ:EOLS) – Equities researchers at HC Wainwright dropped their FY2025 earnings estimates for shares of Evolus in a note issued to investors on Wednesday, March 5th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.23) for the year, down from their previous forecast of $0.11. HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Evolus’ FY2026 earnings at $0.49 EPS, FY2027 earnings at $1.16 EPS, FY2028 earnings at $2.35 EPS and FY2029 earnings at $3.81 EPS.

Other research analysts have also issued research reports about the stock. Barclays lifted their price objective on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Evolus in a report on Wednesday, March 5th.

Evolus Stock Up 0.2 %

Evolus stock opened at $12.71 on Monday. The company’s 50 day simple moving average is $12.98 and its 200 day simple moving average is $14.03. Evolus has a fifty-two week low of $9.25 and a fifty-two week high of $17.82. The firm has a market capitalization of $808.19 million, a price-to-earnings ratio of -13.97 and a beta of 1.28. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23.

Hedge Funds Weigh In On Evolus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tang Capital Management LLC boosted its position in Evolus by 3.1% during the fourth quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock worth $55,171,000 after purchasing an additional 150,000 shares during the period. Nantahala Capital Management LLC boosted its position in Evolus by 10.8% during the fourth quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock worth $34,557,000 after purchasing an additional 305,300 shares during the period. Caligan Partners LP boosted its position in Evolus by 22.7% during the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock worth $29,724,000 after purchasing an additional 498,900 shares during the period. Millennium Management LLC boosted its position in shares of Evolus by 29.1% in the fourth quarter. Millennium Management LLC now owns 1,368,423 shares of the company’s stock valued at $15,107,000 after acquiring an additional 308,753 shares during the period. Finally, Boothbay Fund Management LLC boosted its position in shares of Evolus by 30.9% in the fourth quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company’s stock valued at $14,217,000 after acquiring an additional 304,065 shares during the period. 90.69% of the stock is owned by institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.